<DOC>
	<DOCNO>NCT00932971</DOCNO>
	<brief_summary>Randomized , double blind study compare efficacy pegylated interferon-alfa2a plus placebo versus pegylated interferon-alfa2a plus tenofovir treatment chronic delta hepatitis . 70 Patients randomize 1:1 two group . Treatment duration : 96 week . Follow-up : 24 week . Long-term-follow-up : week 358 .</brief_summary>
	<brief_title>HIDIT II - PegIFN-alfa2a Plus Tenofovir Chronic Delta Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Written inform consent . Age &gt; 18 year . Positive HBsAg , least prior 6 month , positive antiHDV least 3 month positive HDVRNA PCR within screen period . Elevated serum ALT ≥ ULN ≤ 10X ULN determine two abnormal value take &gt; 1 month apart 12 month first dose study drug least one determination obtain ≤ 35 day prior first dose . A liver biopsy obtain within past 12 month demonstrate liver disease consistent chronic hepatitis . Patients cirrhosis liver biopsy must also liver image investigation rule hepatic carcinoma . Negative urine serum pregnancy test document within 24 hour period prior first dose test drug . Additionally , fertile male partner childbearing age female use two reliable form effective contraception ( combine ) throughout entire period study ( treatment 4 month treatment completion ) Creatinine clearance ≥ 70 mL/min Patients must receive antiviral therapy chronic hepatitis D within previous 6 month . Patients expect need systemic antiviral therapy provide study time participation study also exclude . Positive test screening HAVAgIgM , HCVRNA HCVAg HIVAg . Serum concentration ceruloplasmin alpha1antitrypsin consistent increase risk metabolic liver disease . Evidence decompensated liver disease ( Childs BC ) . History evidence medical condition associate chronic liver disease ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure , thalassemia ) . Women ongoing pregnancy breast feeding . WBC count &lt; 3.000 cells/ mm3 ; neutrophil count &lt; 1.500 cells/mm3or platelet count &lt; 90.000 cells/mm3 . Evidence alcohol and/or drug abuse within one year entry . Patients exclude history psychiatric disease , especially depression , suicidal attempt evident . History immunologically mediate disease . History evidence decompensated liver disease . History evidence chronic pulmonary disease associate functional limitation . History severe cardiac disease Evidence active suspect cancer history malignancy risk cancer recur . History receive systemic antineoplastic ( include radiation ) immunomodulatory treatment ( include systemic corticosteroid ) ≤ 6 month prior first dose study drug expectation treatment need time study . History organ transplantation exist functional graft History thyroid disease poorly control prescribed medication . Patients elevate thyroid stimulate hormone concentration elevation antibody thyroid peroxidase clinical manifestation thyroid disease exclude . History evidence severe retinopathy clinically relevant ophthalmological disorder . Inability unwillingness provide inform consent abide requirement study . History evidence severe illness condition would make patient , opinion investigator , unsuitable study . Patients value alphafetoprotein &gt; 100 ng/mL exclude , unless stability ( le 10 % increase ) document least previous 3 month . History evidence intolerance hypersensitivity pegylated interferonalfa2a , tenofovir substance part study medication . Current participation investigational trial participation another investigational trial within 3 month trial begin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>